We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 26

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

The Supreme Court of Canada grants leave to appeal in the Plavix case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 30 2014

The Supreme Court of Canada announced today that it has granted leave to appeal to Apotex Inc. from the Federal Court of Appeal (FCA) in the patent

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Federal court considers “functionally” - limited claims in a biologic case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 22 2014

The Federal Court of Canada recently issued a decision in AbbVie Corporation v. Janssen Inc.,2014 FC 55, involving infringement and validity of a

Biosimilar battlegrounds - what is new in biosimilars and where?

  • Bereskin & Parr LLP
  • -
  • Canada, European Union, USA
  • -
  • February 17 2012

Biosimilars are second entry biologic drugs

Good news for the biotech industry patent eligibility of Myriad isolated DNA and methods of screening claims confirmed after Supreme Court’s Mayo ruling

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • August 20 2012

On August 16, 2012, the U.S. Federal Circuit Court of Appeals issued its judgment in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Myriad) partly overturning the district court’s summary judgment that Myriad’s claims were drawn to patent ineligible subject matter and affirmed Myriad’s right to patent isolated DNA of BRCA1 and BRCA2, two genes linked to breast and ovarian cancer

An update on Canadian selection patents the Olanzapine saga

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • December 15 2011

Eli Lilly’s Canadian patent no. 2,041,113 (‘113 patent), covering its successful drug Olanzapine, has been the subject of several court proceedings, including an infringement action which was appealed and subsequently remanded back to the trial division

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada

  • Bereskin & Parr LLP
  • -
  • Canada, Global
  • -
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the